EntryPoint Capital’s Treace Medical Concepts TMCI Stock Holding History

EntryPoint Capital’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,788	Closed	-$144K	–	960
2024 Q3	$144K	Buy	+24,788	New	+$159K	0.08%	520

Other funds holding TMCI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EntryPoint Capital's TMCI Position: Q4 2024 in Review

EntryPoint Capital sold out of Treace Medical Concepts (TMCI) in Q4 2024, closing a stake of 24,788 shares — an estimated $144K sold.

EntryPoint Capital first reported a position in TMCI in Q3 2024 and held it in 1 quarter. The position peaked at $144K in Q3 2024. 135 funds tracked by Wall St. Rank hold TMCI as of Q4 2024.

EntryPoint Capital reported no remaining Treace Medical Concepts position as of Q4 2024 after selling out during the quarter.
EntryPoint Capital sold 24,788 Treace Medical Concepts shares in Q4 2024, an estimated $144K.
EntryPoint Capital first reported a position in Treace Medical Concepts in Q3 2024 and held it in 1 quarter.
EntryPoint Capital's Treace Medical Concepts position peaked at $144K in Q3 2024.
135 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.